Cognito
Non-Invasive Alzheimer’s Therapy
Cognito leverages insights from optogenetics work done by Li-Hui Tsai and Ed Boyden at MIT. When exposed to gamma frequencies, microglial cells in the brain activate and clear amyloid plaques and tau tangles, two hallmarks of Alzheimer’s.
Cognito has developed a device that administers visual and audio stimulation in this frequency range that is being tested in clinical trials for the symptoms of Alzheimer’s disease.
Neuroelectrics
Transcranial Electric Stimulation for Epilepsy and Depression
Neuroelectrics has developed a proprietary algorithm that uses both EEG data and MRI scans to map individualized brain circuits and deliver customized transcranial electric stimulation therapy to affected regions. The technology is in clinical trials for treatment-resistant epilepsy, of which there are 500,000 patients in the US alone.
The Neuroelectrics headset and software platform is also being tested in trials for depression, ADHD, and Alzheimer’s Disease.
Prilenia Therapeutics
Treating Huntington’s and ALS
Prilenia is a late-stage clinical company that is developing pridopidine, an extremely selective S1R agonist, as a potential treatment for Huntington’s Disease and amyotrophic lateral sclerosis (ALS), two diseases which currently do not have a cure.
Pridopidine positively influences S1R regulated pathways across neurodegenerative and neurodevelopmental indications, including protection against axonal and neuronal injury, restoring spine impairments, enhancing BDNF secretion and restoring mitochondrial function.